ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TXG vs ALMR // 10Y YIELD & FRED MACRO BETA

10x Genomics Inc. (NASDAQ) VS. Alamar Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: TXG 1 — ALMR 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TXG VS. ALMR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TXG ALMR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 69.10% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -5.70% — — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield 1.22% — — TIE /fcf-yield <GO>
Operating Margin -9.50% — — TIE /operating-margins <GO>
Net Profit Margin -6.80% — — TIE /net-margins <GO>
Revenue Growth (YoY) 5.20% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 25.02 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 8/9 — — TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 45.1 50.2 -5.10 ALMR /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE 1.15 — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 24.0x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $9.13B $2.12B $7.01B TXG /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TXG REV ALMR REV TXG GROSS % ALMR GROSS % TXG FCF ALMR FCF
FY 2025 $642.8M $58.8M 69.1% — $130.1M —
FY 2024 $610.8M — 67.9% — -$5.7M —
FY 2023 $618.7M — — — -$43.0M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TXG // BETA 1.15
ALMR // BETA —